menu
    • menu
    [{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"ISD017","moa":"STING","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISD Immunotech \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Biogen"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ISD017","moa":"STING","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISD Immunotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by ISD Immunotech

    Menu

    ISD Immunotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ISD Immunotech

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            ISD Immunotech

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISD017

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ISD Immunotech Granted US and EU Patents for Novel Severe Systemic Lupus Erythematosus (SLE) Therapy Candidate...

                            Details : US patent covering the lead candidate ISD017, which uniquely blocks all aspects of STING pathway overactivation in severe systemic lupus erythematosus (SLE) patients.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 26, 2021

                            Lead Product(s) : ISD017

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ISD Immunotech

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            ISD Immunotech

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISD017

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Biogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of...

                            Details : ISD and Biogen will work together to develop ISD's lead compound, ISD 017, which is being developed to treat severe lupus - systemic lupus erythematosus (SLE).

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 23, 2020

                            Lead Product(s) : ISD017

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Biogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth